Associated Papers
KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges.
Vitiello PP et al.
Cancers, 2025
[Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer].
Shi J et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2025
Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.
Kuo CY et al.
Journal of Chemotherapy (florence, Italy), 2025
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.
Chen Y et al.
Molecular Cancer Therapeutics, 2025
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.
Liguori L et al.
Critical Reviews in Oncology/hematology, 2025
Comprehensive analysis of KRAS aberrations in pan-cancer, with a focus on prognostic and therapeutic implications.
Jung J et al.
Therapeutic Advances in Medical Oncology, 2025
The structure of KRASG12C bound to divarasib highlights features of potent switch-II pocket engagement.
Fernando MC et al.
Small Gtpases, 2024
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.
Yang X et al.
Journal of Hematology & Oncology, 2024
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.
Fukuda K et al.
Cell Reports. Medicine, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
Jiang J et al.
Cancer Discovery, 2024
Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis.
Disel U et al.
The Oncologist, 2024
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.
Nussinov R et al.
Annual Review of Pharmacology and Toxicology, 2024
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies.
Linehan A et al.
Frontiers in Medicine, 2024
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer.
Chour A et al.
Frontiers in Oncology, 2024
Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.
Guo Y et al.
Cell Reports, 2023
Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer.
Liu J et al.
Cancers, 2023
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.
Yang H et al.
Cancer Communications (london, England), 2023
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J et al.
Pathology Oncology Research : Por, 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M et al.
Current Treatment Options in Oncology, 2022
Does Molecular Profiling of KRAS-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?
Karim NA et al.
Current Oncology (toronto, Ont.), 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A et al.
Cancer Discovery, 2022
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.
Feng S et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Hofmann MH et al.
Cancer Discovery, 2022
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.
Reita D et al.
Cancers, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Targeting KRAS G12C mutation in lung adenocarcinoma.
Rohatgi A et al.
Lung Cancer (amsterdam, Netherlands), 2022
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T et al.
Scientific Reports, 2022
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.
Kwan AK et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2022
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation.
Li Y et al.
Computational and Structural Biotechnology Journal, 2022
Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C.
Zhuang H et al.
Frontiers in Oncology, 2022
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer.
Ricciuti B et al.
Drugs in Context, 2022
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.
Ritu K et al.
Molecular Biomedicine, 2021
Anticancer drug resistance: An update and perspective.
Nussinov R et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2021
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D et al.
Molecular Cancer, 2021
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacological Research, 2021
Emerging strategies to target RAS signaling in human cancer therapy.
Chen K et al.
Journal of Hematology & Oncology, 2021
Acquired Resistance to KRASG12C Inhibition in Cancer.
Awad MM et al.
The New England Journal of Medicine, 2021